

EUROPEAN
CURRICULUM VITAE



PERSONAL INFORMATIONS

Name	ALESSANDRA TEDESCHI
Address	PIAZZA OSPEDALE MAGGIORE ,3 MILANO
Telephone	00390264442668
Fax	00390264442033
E-mail	alessandra.tedeschi@ospedaleniguarda.it
Social Security Number	TDSLSN64T46H501H
Nazionalità	Italian
Date and place of bearth	06/12/1964, ROMA ITALY

WORK EXPERIENCE

• Dates (from – to)	From April 1999-today
Main activities and responsibilities	Consultant in Haematology at the Department of Oncology/Haematology Division of Haematology ASST Grande Ospedale Metropolitano Niguarda
Name and address of employer	Clinical care of patients affected by Chronic Lymphocytic Leukemia and indolent non follicular Lymphoproliferative disorders Principal investigator in National and International clinical trials in Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia ASST Grande Ospedale Metropolitano Niguarda
• Dates (from – to)	July 1997-March 1999
• Main activities and responsibilities	Research stage on a project regarding the purging of peripheral blood stem cell transplant in lymphoproliferative disorders at the Department of Haematology ASST Grande Ospedale Metropolitano Niguarda
Name and address of employer	ASST Grande Ospedale Metropolitano Niguarda
• Date (from – to)	November 1996-July 1997
• Main activities and responsibilities	Research stage on a project Research stage on a project regarding cord blood transplants in Hematological malignancies at the Department of Haematology of ASST Grande Ospedale Metropolitano Niguarda
Name and address of employer	ASST Grande Ospedale Metropolitano Niguarda

EDUCATION and TRAINING

• Date	1998
• Main activities and responsibilities	Research stage at the MD Anderson Cancer Center, Houston, Texas on Chronic Lymphocytic leukemia
• Dates (from-to)	1992-1996
Name and Type of organization providing education and training	Fellowship in Haematology at the Ancona University Medical School. University of Ancona Italy

• Date	1996
Title and qualification awarded	PhD on Clinical Haematology
Name and Type of organization providing education and training	University of Ancona Italy
• Date	Accademic year 1989/90
Title and qualification awarded	Medical Doctor Degree
Name and Type of organization providing education and training	Bologna University Medical School
MOTHER TONGUE	ITALIAN
OTHER LANGUAGES	ENGLISG GREEK
• Capacità di lettura	excellent
• Capacità di scrittura	good
• Capacità di espressione orale	excellent
SOCIAL SKIILS AND COMPETENCE	Prolonged experience in the management of patients affected by hematological malignancies in daily activity as well as in the context of experimental clinical trials Great skills in working together with other people and in organizing clinical activities for in and out patients care and in clinical research environment

Milano, 13 February 2017

Dr. Alessandra Tedeschi



PUBLICATIONS

1 Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.

Montillo M, O'Brien S, **Tedeschi A**, Byrd JC, Dearden C, Gill D, Brown JR, Barrientos JC, Mulligan SP, Furman RR, Cymbalista F, Plascencia C, Chang S, Hsu E, James DF, Hillmen P.
Blood Cancer J. 2017 Feb 3;7(2):e524. doi: 10.1038/bcj.2017.5

2 Front-line treatment of CLL in the era of novel agents.

Robak T, Stilgenbauer S, **Tedeschi A**.
Cancer Treat Rev. 2017 Feb;53:70-78

3 Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

Dimopoulos MA, Trotman J, **Tedeschi A**, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsenis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia..
Lancet Oncol. 2016 Dec 9. pii: S1470-2045(16)30632-5

4 BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.

Gavriatopoulou M, García-Sanz R, Kastritis E, Morel P, Kyrtsenis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, **Tedeschi A**, Gika D, Merlini G, Sonneveld P, Dimopoulos MA.
Blood. 2017 Jan 26;129(4):456-459

5 A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.

Chiaretti S, Vitale A, Vignetti M, Piciocchi A, Fazi P, Elia L, Falini B, Ronco F, Ferrara F, De Fabritiis P, Luppi M, La Nasa G, **Tedeschi A**, Califano C, Fanin R, Dore F, Mandelli F, Meloni G, Foà R.
Haematologica. 2016 Dec;101(12):1544-1552

6 Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia of COMPLEMENT-1 and other monoclonal antibodies association data

Frustaci AM, **Tedeschi A**, Picardi P, Mazzucchelli M, Cairoli R, Montillo M.
Ther Adv Hematol. 2016 Aug;7(4):222-30

7 Paving the way for new agents is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?

Frustaci AM, Montillo M, Picardi P, Mazzucchelli M, Cairoli R, **Tedeschi A**.
Expert Rev Hematol. 2016 Jul;9(7):679-93

8 Bing Neel Syndrome in a previously untreated patients with Waldenstrom's Macroglobulinemia contribution of MYD 88 L265P mutation on cerebrospinal fluid

Frustaci AM, Rusconi C, Picardi P, Veronese S, Montillo M, Cairoli R, **Tedeschi A**.
Clin Lymphoma Myeloma Leuk. 2016 Jan;16(1):e7-9

9 Central nervous system involvement by Waldenstrom's Macroglobulinemia (Bing Neel Syndrome) a multi-institutional retrospective study

Castillo JJ, D'Sa S, Lunn MP, Minnema MC, **Tedeschi A**, Lansigan F, Palomba ML, Varettoni M, Garcia-Sanz R, Nayak L, Lee EQ, Rinne ML, Norden AD, Ghobrial IM, Treon SP. Br J Haematol. 2016 Mar;172(5):709-15. doi: 10.1111/bjh.13883.

10 Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Xu L, Hunter ZR, Tsakmaklis N, Cao Y, Yang G, Chen J, Liu X, Kanan S, Castillo JJ, Tai YT, Zehnder JL, Brown JR, Carrasco RD, Advani R, Sabile JM, Argyropoulos K, Lia Palomba M, Morra E, Trojani A, Greco A, **Tedeschi A**, Varettoni M, Arcaini L, Munshi NM, Anderson KC, Treon SP. Br J Haematol. 2016 Mar;172(5):735-44. doi: 10.1111/bjh.13897.

11 Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. Burger JA, **Tedeschi A**, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators.. N Engl J Med. 2015 Dec 17;373(25):2425-37

12 Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia. Frustaci AM, **Tedeschi A**, Picardi P, Cairoli R, Montillo M. Biologics: targets & therapy.2015;9:75-86

13 A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular non-Hodgkin's Lymphoma. Luminari S, Goldaniga M, Cesaretti M, Orsucci L, Tucci A, Pulsoni A, Salvi F, Arcaini L, Carella AM, **Tedeschi A**, Pinto A, Stelitano C, Baldini L. Leukemia & lymphoma .2015;17:1-31

14 Toll-Like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling activation and proliferation. Fonte E, Agathangelidis A, Reverberi D, Ntoufa S, Scarfò L, Raghetti P, Cutrona G, **Tedeschi A**, Xochelli A, Caligaris-Cappio F, Ponzoni M, Belessi C, Davis Z, Piris MA, Oscier D, Ghia P, Stamatopoulos K, Muzio M. Haematologica ,2015;100:1460-1468

15 A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. **Tedeschi A**, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortelezzi A, Nador G, Scarfò L, Cairoli R, Frustaci AM, Dalceggio D, Picardi P, De Paoli L, Orlandi E, Rambaldi A, Massaia M, Gaidano G, Montillo M. Haematologica ,2015;100:501-504

16 Molecular prediction of durable response after first line fludarabine cyclophosphamide rituximab in CLL. Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, Del Giudice I, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, **Tedeschi A**, Neri A, Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M, Cuneo A, Gattei V, Foà R, Gaidano G. Blood, 2015; 126(16):1921-4

17 Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. **Tedeschi A**, Picardi P, Ferrero S, Benevolo G, Margiotta Casaluci G, Varettoni M, Baratè C, Motta M, Gini G, Goldaniga MC, Visco C, Zaja F, Belsito Petrizi V, Ravelli E, Gentile M, Urbano MA, Franceschetti S, Ghione P, Orsucci L, Frustaci AM, Gaidano G, Vitolo U, Morra E. Leuk Lymphoma. 2015;14:1-6

18 Immunoglobulin heavy variable (IGHV) genes and alleles: new entities new names and implications for research and prognostication in chronic lymphocytic leukemia. Xochelli A, Agathangelidis A, Kavakiotis I, Minga E, Sutton LA, Baliakas P, Chouvarda I, Giudicelli V, Vlahavas I, Maglaveras N, Bonello L, Trentin L, **Tedeschi A**, Panagiotidis P, Geisler C, Langerak AW,

Pospisilova S, Jelinek DF, Oscier D, Chiorazzi N, Darzentas N, Davi F, Ghia P, Rosenquist R, Hadzidimitriou A, Belessi C, Lefranc MP, Stamatopoulos K. Immunogenetics. 2015;67(1):61-6.

19 Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients

Montillo M, **Tedeschi A**, Gaidano G, Coscia M, Petrizzi VB, Orlandi E, Cascavilla N, Ghia P, Motta M, Gallamini A, Frustaci AM, Rossi D, De Paoli L, Nichelatti M, Morra E, Massaia M. Haematologica. 2014;99(9):e159-61.

20 Associated cancers in Waldenstrom Macroglobulinemia: clues for common genetic predisposition

Morra E, Varettoni M, **Tedeschi A**, Arcaini L, Ricci F, Pascutto C, Rattotti S, Vismara E, Paris L, Cazzola M. Clin Lymphoma Myeloma Leuk. 2013;13(6):700-3

21 Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).

Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M, Morel P, Kyrtsolis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, **Tedeschi A**, Gika D, Merlini G, Kastritis E, Sonneveld P. Blood. 2013;122(19):3276-82.

22 Use it again: retherapy with bendamustine in indolent B-cell lymphoproliferative disorders

Montillo M, **Tedeschi A**. Expert Rev Hematol. 2013 Jun;6(3):247-50

23 Should a positive direct antiglobulin test be considered a prognostic predictor in chronic lymphocytic leukemia?

Ricci F, **Tedeschi A**, Vismara E, Colombo C, Veronese S, Nichelatti M, Cairoli R, Morra E, Montillo M. Clin Lymphoma Myeloma Leuk. 2013;13(4):441-6

24 Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts.

Chiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P, Valsecchi MG, Elia L, Testi AM, Mancini F, Conter V, te Kronnie G, Ferrara F, Di Raimondo F, **Tedeschi A**, Fioritoni G, Fabbiano F, Meloni G, Specchia G, Pizzolo G, Mandelli F, Guarini A, Basso G, Biondi A, Foà R. Haematologica. 2013;98(11):1702-10

25 Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia.

Tedeschi A, Ricci F, Goldaniga MC, Benevolo G, Varettoni M, Motta M, Pioltelli P, Gini G, Barate' C, Luraschi A, Vismara E, Frustaci AM, Nichelatti M, Vitolo U, Baldini L, Morra E. Clin Lymphoma Myeloma Leuk. 2013;13(2):231-4

26 Microarray demonstrates different gene expression profiling signatures between Waldenström macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.

Trojani A, Greco A, **Tedeschi A**, Lodola M, Di Camillo B, Ricci F, Turrini M, Varettoni M, Rattotti S, Morra E. Clin Lymphoma Myeloma Leuk. 2013;13(2):208-10.

27 Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.

Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, Garcia-Sanz R, Ocio EM, Morra E, Morel P, Anderson KC, Patterson CJ, Munshi NC, **Tedeschi A**, Joshua DE, Kastritis E, Terpos E, Ghobrial IM, Leleu X, Gertz MA, Ansell SM, Morice WG, Kimby E, Treon SP; VIth International Workshop on Waldenström macroglobulinaemia. Br J Haematol. 2013;160(2):171-6.

28 Impact of B-cell count and imaging screening in cMBL: any need to revise the current guidelines?

Scarfò L, Zibellini S, **Tedeschi A**, Maura F, Neri A, Bertazzoni P, Sarina B, Nalli G, Motta M, Rossini F, Cortelezzi A, Montillo M, Orlandi E, Ghia P. Leukemia. 2012;26(7):1703-7

29 Fludarabine Cyclophosphamide and rituximab in patients with advanced untreated indolent B-cell non follicular lymphomas: phase 2 studi of the Italian Lymphoma Foundation

- Ferrario A, Pulsoni A, Olivero B, Rossi G, Vitolo U, **Tedeschi A**, Merli F, Rigacci L, Stelitano C, Goldaniga M, Mannina D, Musto P, Rossi F, Gamba E, Baldini L.
Cancer. 2012;118(16):3954-61
- 30 *The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms: a retrospective multicentric GIMEMA experience.*
Laurenti L, Tarnani M, Nichele I, Ciolli S, Cortelezzi A, Forconi F, Rossi D, Mauro FR, D'Arena G, Del Poeta G, Montanaro M, Morabito F, Musolino C, Callea V, Falchi L, **Tedeschi A**, Ambrosetti A, Gaidano G, Leone G, Foà R.
Am J Hematol. 2011;86(12):1007-12.
- 31 *Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom's Macroglobulinemia.*
Ricci F, **Tedeschi A**, Montillo M, Morra E.
Mediterr J Hematol Infect Dis. 2011;3(1)
- 32 *An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.*
Montillo M, **Tedeschi A**, Petrizzi VB, Ricci F, Crugnola M, Spriano M, Spedini P, Ilariucci F, Uziel L, Attolico I, Vismara E, De Blasio A, Zaccaria A, Morra E.
Blood. 2011;118(15):4079-85
- 33 *Three copies of isochromosome 8q in Ph+ B-cell acute lymphoblastic leukemia.*
Soriani S, Fedeli F, Molteni A, Grillo G, **Tedeschi A**, Scarpati B, Campidelli C, Leszl A, Farioli R, De Canal G, Mura MA, Cesana C.
Leuk Res. 2011;35(11):e217-9
- 34 *Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease.*
Tedeschi A, Benevolo G, Varettoni M, Battista ML, Zinzani PL, Visco C, Meneghini V, Pioltelli P, Sacchi S, Ricci F, Nichelatti M, Zaja F, Lazzarino M, Vitolo U, Morra E.
Cancer. 2012; 118(2):434-43
- 35 *Risk of second cancers in Waldenström macroglobulinemia.*
Varettoni M, **Tedeschi A**, Arcaini L, Pascutto C, Vismara E, Orlandi E, Ricci F, Corso A, Greco A, Mangiacavalli S, Lazzarino M, Morra E.
Ann Oncol. 2012;23(2):411-5
- 36 *The impact of advanced age according to IPSSWM cut-off on the outcome of symptomatic and asymptomatic Waldenström's macroglobulinemia at diagnosis.*
Ricci F, **Tedeschi A**, Vismara E, Greco A, Montillo M, Nichelatti M, Varettoni M, Lazzarino M, Morra E.
Clin Lymphoma Myeloma Leuk. 2011;11(1):124-6
- 37 *Factors predicting transformation of asymptomatic IgM monoclonal gammopathy.*
Greco A, **Tedeschi A**, Varettoni M, Nichelatti M, Paris L, Ricci F, Vismara E, Morra E.
Clin Lymphoma Myeloma Leuk. 2011;11(1):77-9
- 38 *Relationship between pharmacokinetic profile of subcutaneous alemtuzumab and clinical response in patients with chronic lymphocytic leukemia*
Montagna M, Montillo M, Avanzini MA, Tinelli C, **Tedeschi A**, Visai L, Ricci F, Vismara E, Morra E, Regazzi M.
Haematologica. 2011;96(6):932-6
- 39 *The spectrum of use of rituximab in chronic lymphocytic leukemia*
Tedeschi A, Vismara E, Ricci F, Morra E, Montillo M.
Onco Targets Ther. 2010;3:227-46
- 40 *Gene expression profiling identifies ARSD as a new marker of disease progression and the sphingolipid metabolism as a potential novel metabolism in chronic lymphocytic leukemia*
Trojani A, Di Camillo B, **Tedeschi A**, Lodola M, Montesano S, Ricci F, Vismara E, Greco A, Veronese S, Orlicchio A, Martino S, Colombo C, Mura M, Nichelatti M, Colosimo A, Scarpati B, Montillo M, Morra E.
Cancer Biomark. 2011-2012;11(1):15-28

- 41 *Bendamustine new perspective for an old drug in lymphoproliferative disorders*
Montillo M, Ricci F, **Tedeschi A**, Vismara E, Morra E.
Expert Rev Hematol. 2010 Apr;3(2):131-48
- 42 *ZAP-70 IgVH and cytogenetics for assessing prognosis in chronic lymphocytic leukemia*
Trojani A, Montillo M, Nichelatti M, **Tedeschi A**, Colombo C, Veronese S, Mura MA, Ricci F, Scarpati B, Colosimo A, Lodola M, Morra E.
Cancer Biomark. 2010;6(1):1-9
- 43 *Fludarabine in the treatment of chronic lymphocytic leukemia a review*
Ricci F, **Tedeschi A**, Morra E, Montillo M.
Ther Clin Risk Manag. 2009;5(1):187-207
- 44 *Fludarabine-based combination therapies for Waldenström's Macroglobulinemia*
Tedeschi A, Alamos SM, Ricci F, Greco A, Morra E.
Clin Lymphoma Myeloma. 2009;9(1):67-70
- 45 *Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.*
Montillo M, Ricci F, **Tedeschi A**, Cafrò AM, Nosari AM, Nichelatti M, Marbello L, Morra E.
Leuk Res. 2009;33(8):1072-8
- 46 *Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature.*
Marbello L, Ricci F, Nosari AM, Turrini M, Nador G, Nichelatti M, **Tedeschi A**, Vismara E, Morra E.
Leuk Res. 2008;32(8):1221-7.
- 47 *Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL).*
Montillo M, Ricci F, Miqueleiz S, **Tedeschi A**, Morra E.
Biologics. 2008;2(1):41-52
- 48 *Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab.*
Nosari A, **Tedeschi A**, Ricci F, Montillo M.
Haematologica. 2008;93(2):e30-1
- 49 *Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.*
Molica S, Montillo M, Ribatti D, Mirabelli R, **Tedeschi A**, Ricci F, Veronese S, Vacca A, Morra E.
Haematologica. 2007;92(10):1367-74
- 50 *Cryoglobulinemia.*
Tedeschi A, Baratè C, Minola E, Morra E.
Blood Rev. 2007;21(4):183-200.
- 51 *High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.*
Tedeschi A, Montillo M, Strocchi E, Cafrò AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E.
Cancer Chemother Pharmacol. 2007;59(6):771-9
- 52 *Role of fludarabine in hematological malignancies.*
Montillo M, Ricci F, **Tedeschi A**.
Expert Rev Anticancer Ther. 2006;6(9):1141-61
- 53 *Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.*
Montillo M, **Tedeschi A**, Miqueleiz S, Veronese S, Cairoli R, Intropido L, Ricci F, Colosimo A, Scarpati B, Montagna M, Nichelatti M, Regazzi M, Morra E.
J Clin Oncol. 2006;24(15):2337-42.
- 54 *The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial.*

Cimino G, Pane F, Elia L, Finolezzi E, Fazi P, Annino L, Meloni G, Mancini M, **Tedeschi A**, Di Raimondo F, Specchia G, Fioritoni G, Leoni P, Cuneo A, Mecucci C, Saglio G, Mandelli F, Foà R; GIMEMA Leukemia Working Party. *Haematologica*. 2006;91(3):377-80

55 *A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol.*

Mancini M, Scappaticci D, Cimino G, Nanni M, Derme V, Elia L, Tafuri A, Vignetti M, Vitale A, Cuneo A, Castoldi G, Saglio G, Pane F, Mecucci C, Camera A, Specchia G, **Tedeschi A**, Di Raimondo F, Fioritoni G, Fabbiano F, Marmont F, Ferrara F, Cascavilla N, Todeschini G, Nobile F, Kropp MG, Leoni P, Tabilio A, Luppi M, Annino L, Mandelli F, Foà R. *Blood*. 2005;105(9):3434-41

56 *High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation.*

Cairolì R, Grillo G, Tedeschi A, D'Avanzo G, Marengo P, Morra E. *Haematologica*. 2004;89(3):361-3

57 *Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H.*

Montillo M, **Tedeschi A**, Rossi V, Cairolì R, Pungolino E, Intropido L, Cafrò AM, D'Avanzo G, Farioli R, Brando B, Scarpati B, Veronese S, Morra E. *Leukemia*. 2004;18(1):57-62

58 *C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index.*

Cairolì R, Grillo G, Beghini A, **Tedeschi A**, Ripamonti CB, Larizza L, Morra E. *Leukemia*. 2003;17(2):471-2. No abstract available.

59 *Interphase fluorescence in situ hybridization analysis of del(11)(q23) and del(17)(p13) in chronic lymphocytic leukemia. a study of 40 early-onset patients.*

Doneda L, Montillo M, Intropido L, **Tedeschi A**, Morra E, Larizza L. *Cancer Genet Cytogenet*. 2003;140(1):31-6

60 *Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia.*

Montillo M, **Tedeschi A**, O'Brien S, Di Raimondo F, Lerner S, Ferrajoli A, Morra E, Keating MJ. *Cancer*. 2003;97(1):114-20

61 *Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation.*

Tedeschi A, Cairolì R, Marengo P, Nosari A, Tresoldi E, Di Bona E, Montillo M, Morra E. *Leukemia*. 2002;16(12):2455-6

62 *Partial deletions of long arm of chromosome 6: biologic and clinical implications in adult acute lymphoblastic leukemia.*

Mancini M, Vegna ML, Castoldi GL, Mecucci C, Spirito F, Elia L, Tafuri A, Annino L, Pane F, Rege-Cambrin G, Gottardi M, Leoni P, Gallo E, Camera A, Luciano L, Specchia G, Torelli G, Sborgia M, Gabbas A, **Tedeschi A**, Della Starza I, Cascavilla N, Di Raimondo F, Mandelli F, Foà R. *Leukemia*. 2002;16(10):2055-61.

63 *MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia.*

Tafuri A, Gregorj C, Petrucci MT, Ricciardi MR, Mancini M, Cimino G, Mecucci C, **Tedeschi A**, Fioritoni G, Ferrara F, Di Raimondo F, Gallo E, Liso V, Fabbiano F, Cascavilla N, Pizzolo G, Camera A, Pane F, Lanza F, Cilloni D, Annino L, Vitale A, Vegna ML, Vignetti M, Foà R, Mandelli F; GIMEMA Group. *Blood*. 2002;100(3):974-81.

64 *Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.*

Montillo M, Cafrò AM, **Tedeschi A**, Brando B, Oreste P, Veronese S, Rossi V, Cairolì R, Pungolino E, Morra E. *Haematologica*. 2002;87(7):695-700

65 *Prior invasive pulmonary and cerebellar mucormycosis is not a primary contraindication to perform an autologous stem cell transplantation in leukemia.*

Tedeschi A, Montillo M, Cairoli R, Marengo P, Cafro A, Oreste P, Nosari A, Morra E.
Leuk Lymphoma. 2002;43(3):657-9.

66 *Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis.*

Cairoli R, Grillo G, **Tedeschi A**, Gargantini L, Marengo P, Tresoldi E, Barbarano L, Nosari AM, Morra E.
Bone Marrow Transplant. 2002;29(6):473-7

67 *The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease.*

DiRaimondo F, Albitar M, Huh Y, O'Brien S, Montillo M, **Tedeschi A**, Kantarjian H, Lerner S, Giustolisi R, Keating M.
Cancer. 2002;94(6):1721-30.

68 *Detection of BCR/ABL rearrangements in adult acute lymphoblastic leukemia using a highly sensitive interphase fluorescence in situ hybridization method (D-FISH).*

Mancini M, Nanni M, Sirleto P, De Cuia MR, Castoldi GL, Cilloni D, Cimino G, Mecucci C, Pane F, Annino L, Di Raimondo F, Santoro A, Specchia G, **Tedeschi A**, Todeschini G, Foà R; GIMEMA study group.
Hematol J. 2001;2(1):54-60

69 *Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion.*

Nosari A, Oreste P, Cairoli R, Montillo M, Carrafiello G, Astolfi A, Muti G, Marbello L, **Tedeschi A**, Magliano E, Morra E.
Am J Hematol. 2001;68(4):231-6

70 *Multicolor FISH in chronic lymphocytic leukemia. An interphase study of patients with early-onset disease.*

Doneda L, Castorina P, Tedeschi A, Intropido L, Morra E, Montillo M, Larizza L.
Cancer Genet Cytogenet. 2001;125(1):63-9

71 *Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the Gimema Group.* Gruppo Italiano Malattie Ematologiche Maligne Dell'Adulto.

Montillo M, **Tedeschi A**, Pagano L, Venditti A, Ferrara F, Fabris P, Martino B, Musso M, De Rosa G, Specchia G, Monaco M, Sparaventi G, Spadea A, Palmas A, Deplano W, Manna A, Melillo L, Miraglia E, Mirto S, Mandelli F.
Br J Haematol. 2000;111(1):334-7

72 *Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG).*

Tedeschi A, Montillo M, Ferrara F, Nosari A, Mele G, Copia C, Leoni P, Morra E.
Eur J Haematol. 2000;64(3):182-7

73 *Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma.*

Lazzarino M, Orlandi E, Montillo M, **Tedeschi A**, Pagnucco G, Astori C, Corso A, Brusamolino E, Simoncini L, Morra E, Bernasconi C.
Ann Oncol. 1999;10(1):59-64

74 *Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia.*

Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A, Zagonel V, Mele G, **Tedeschi A**, Ferrara F.
Am J Hematol. 1998;58(2):105-9

75 *Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF).*

Montillo M, **Tedeschi A**, Centurioni R, Leoni P.
Leuk Lymphoma. 1997;25(5-6):579-83

76 Effectiveness of fludarabine in advanced B-cell chronic lymphocytic leukemia.

Montillo M, **Tedeschi A**, Delfini C, Olivieri A, D'Adamo F, Leoni P.

Tumori. 1995;81(6):419-23

77 Acute renal failure as a consequence of urine stop flow in a patient with chronic lymphocytic leukemia after treatment with fludarabine.

Montillo M, **Tedeschi A**, Leoni P.

Am J Hematol. 1995;50(1):73-4.

78 Recurrence of autoimmune thrombocytopenia after treatment with fludarabine in a patient with chronic lymphocytic leukemia.

Montillo M, **Tedeschi A**, Leoni P.

Leuk Lymphoma. 1994;15(1-2):187-8

79 PBSC collection after high dose chemotherapy followed by G-CSF in patients with malignancies: analysis of results regarding factors affecting the yield of hemopoietic progenitors.

Olivieri A, Offidani M, Ciniero L, Poloni A, **Tedeschi A**, Refe MC, Strusi AS, Leoni P.

Int J Artif Organs. 1993 ;16 Suppl 5:57-63

Handwritten signature